Skip to main content
SupplementScience

Pelargonium (Umcka) Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

Pelargonium sidoides has an unusually strong evidence base for a herbal remedy. The Cochrane review by Timmer et al. (2013) analyzed 10 RCTs and concluded that EPs 7630 is effective and well-tolerated for acute bronchitis. Matthys et al. (2003) conducted a pivotal double-blind, placebo-controlled RCT showing significant reductions in bronchitis symptom severity scores after 7 days of treatment. The extract is approved as a licensed phytomedicine in Germany — a regulatory status that requires demonstration of efficacy and safety through clinical trials. The multi-target mechanism (antiviral, antibacterial, immunomodulatory, mucociliary) provides a pharmacological rationale for its clinical effectiveness.

Evidence by Condition

ConditionStudied DoseEvidence
Acute bronchitis20mg tablet or 30 drops liquid 3x daily for 7-14 daysModerate
Acute cold/URI20mg 3x daily started within 48 hours of symptom onsetModerate
Children (6-12 years)10-20mg 3x daily for 7 daysModerate

References

  1. (). Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database of Systematic Reviews. DOI
  2. (). Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. Phytomedicine. DOI